or Try an Advanced Search...

    Technical Analysis for RCE - Recce Ltd  

    Grade Last Price % Change Price Change
    D 0.470 2.17% 0.010
    RCE closed up 2.17 percent on Thursday, November 21, 2024, on 44 percent of normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical RCE trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    Gapped Up Strength 0.00%
    20 DMA Resistance Bearish 2.17%
    Gapped Up Strength 2.17%
    Gapped Down Weakness 2.17%
    Fell Below 20 DMA Bearish -2.08%
    Overbought Stochastic Strength -2.08%
    200 DMA Resistance Bearish -6.00%
    50 DMA Resistance Bearish -6.00%
    1,2,3 Retracement Bearish Bearish Swing Setup -6.00%
    Older End-of-Day Signals for RCE ...

       Recent Intraday Alerts

    Alert Time
    Reversed from Up about 13 hours ago
    Gap Up Closed about 14 hours ago
    Gapped Up (Full) about 16 hours ago
    20 DMA Resistance about 16 hours ago
    10 DMA Resistance about 16 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    RCE Chart by TradingView
    Basic chart:

    Profile

    Recce Ltd   Description

    Recce Limited is an Australia-based research-based pharmaceutical company. The Company is principally engaged in research and development of antibiotic drugs and anticancer drugs. The Company's antibiotics kill both susceptible bacteria and drug resistant super bugs throughout the world health danger arising from resistance to present-day antibiotics. The Company offers antibiotic drugs to treat the diseases caused by Sepsis, Helicobacter Pylori (H.Pylori), Escherichia coli (E.coli), Gonorrhea and Tuberculosis (TB). The Company offers anticancer drugs to treat various cancers, such as leukemia, prostate, lung, stomach, intestine, kidney and melanoma. The Company also offers polymer-antibiotics targeted for human use. The Company's Recce antibiotic kills all types of bacteria, including superbugs. Its subsidiaries include Recce (USA) LLP and Recce (UK) Limited.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Major
    Keywords: Health Medicine Pharmaceutical Disease Diseases Cancer Drugs Resistance Cancers Bacteria Pharmaceuticals Policy Bacteriology Antibiotic Chemotherapy Antibiotics Leukemia Melanoma Stomach Veterinary Medicine

    Is RCE a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 12 Recce Pharmaceuticals Receives Ethics Approval in Indonesia to Commence Registrational Phase 3 Trial of RECCE® 327 Topical Gel in Diabetic Foot Infections
    Nov 6 Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections
    Oct 31 Recce Pharmaceuticals Announces Interim Efficacy Data and Safety Approval for Phase II ABSSSI Clinical Trial
    Oct 10 Recce Pharmaceuticals Announces Recruitment Passes Halfway in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections
    Aug 6 Recce Pharmaceuticals Announces Successful Completion of Share Purchase Plan
    Jul 16 Recce Pharmaceuticals Receives $2 Million Grant from U.S. Department of Defense for RECCE® 327 Gel
    Jul 10 Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter baumannii
    Jul 1 Recce Pharmaceuticals Reports Positive Data from Phase I/II Urinary Tract Infection (UTI) / Urosepsis Rapid Infusion Trial of RECCE® 327
    Jun 25 Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections
    Jun 24 Those who invested in Recce Pharmaceuticals (ASX:RCE) five years ago are up 170%
    See more RCE news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 0.695
    52 Week Low 0.38
    Average Volume 169,688
    200-Day Moving Average 0.512
    50-Day Moving Average 0.506
    20-Day Moving Average 0.473
    10-Day Moving Average 0.478
    Average True Range 0.025
    RSI (14) 44.44
    ADX 33.01
    +DI 17.545
    -DI 30.139
    Chandelier Exit (Long, 3 ATRs) 0.486
    Chandelier Exit (Short, 3 ATRs) 0.454
    Upper Bollinger Bands 0.505
    Lower Bollinger Band 0.442
    Percent B (%b) 0.45
    BandWidth 13.184
    MACD Line -0.010
    MACD Signal Line -0.010
    MACD Histogram 0.0007
    Fundamentals Value
    Market Cap 81.61 Million
    Num Shares 174 Million
    EPS -0.03
    Price-to-Earnings (P/E) Ratio -15.67
    Price-to-Sales 0.00
    Price-to-Book 81.46
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.500
    Resistance 3 (R3) 0.500 0.490 0.495
    Resistance 2 (R2) 0.490 0.482 0.490 0.493
    Resistance 1 (R1) 0.480 0.478 0.475 0.480 0.492
    Pivot Point 0.470 0.470 0.468 0.470 0.470
    Support 1 (S1) 0.460 0.462 0.455 0.460 0.448
    Support 2 (S2) 0.450 0.458 0.450 0.447
    Support 3 (S3) 0.440 0.450 0.445
    Support 4 (S4) 0.440